Notably, the LRP1B signature offers insights into the immune microenvironment composition in MM, the response of patients to the proteasome inhibitor bortezomib, and the progression likelihood of Monoclonal Gammopathy of Undetermined Significance (MGUS) to MM. The gene discussed is LRP1B; the disease is Miyoshi myopathy.